Verónica García-Castillo

Dr. Verónica García-Castillo


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2014 in Molecules
Verified
Journal Article
Open access
PDF file
Abraham Pedroza-TorresAbraham Pedroza-Torres
Abraham Pedroza-Torres
Eduardo López-UrrutiaEduardo López-Urrutia
Eduardo López-Urrutia
VGVerónica García-Castillo
Verónica García-Castillo
NJNadia Jacobo-Herrera
Nadia Jacobo-Herrera
LHLuis A. Herrera
Luis A. Herrera
Carlos Pérez-PlasenciaCarlos Pérez-Plasencia
Carlos Pérez-Plasencia
Cervical carcinoma (CC) is one of the most common cancers and a leading cause of mortality in women worldwide. Epidemiologic and experimental data have clearly demonstrated a causal role of high-risk Human Papillomavirus (HR-HPV) types in CC initiation and progression, affecting the cellular processes by targeting and inactivating p53 and pRB host proteins. HR-HPV E5, E6 and E7 oncoproteins have the ability to deregulate several cellular processes, mostly apoptosis, cell cycle control, migration, immune evasion, and induction of genetic instability, which promote the accumulation of mutations and aneuploidy. In this scenario, genomic profiles have shown that aberrant expression of cellular oncogenic and tumor suppressive miRNAs have an important role in CC carcinogenesis. It has been stated that HPV infection and E6/E7 expression are essential but not sufficient to lead to CC development; hence other genetic and epigenetic factors have to be involved in this complex disease. Recent evidence suggests an important level of interaction among E6/E7 viral proteins and cellular miRNA, and other noncoding RNAs. The aim of the current review is to analyze recent data that mainly describe the interaction between HR-HPV established infections and specific cellular miRNAs; moreover, to understand how those interactions could affect radio-therapeutic response in tumor cells.

1 January 2017 in Journal of Cancer
Verified
Journal Article
Open access
VGVerónica García-Castillo
Verónica García-Castillo
Eduardo López-UrrutiaEduardo López-Urrutia
Eduardo López-Urrutia
OVOctavio Villanueva-Sánchez
Octavio Villanueva-Sánchez
MÁMiguel Á. Ávila-Rodríguez
Miguel Á. Ávila-Rodríguez
AZAlejandro Zentella-Dehesa
Alejandro Zentella-Dehesa
Carlos Pérez-PlasenciaCarlos Pérez-Plasencia
Carlos Pérez-Plasencia
Background: Chemotherapy is the backbone of systemic treatment for triple negative breast cancer (TNBC), which is one of the most relevant breast cancers molecular types due to the ability of tumor cells to develop drug resistance, highlighting the urgent need to design newer and safer drug combinations for treatment. In this context, to overcome tumor cell drug resistance, we employed a novel combinatorial treatment including Doxorubicin, Metformin, and Sodium Oxamate (DoxMetOx). Such pharmacological combination targets indispensable hallmarks of cancer-related to aerobic glycolysis and DNA synthesis.

Verified
Journal Article
Open access
PDF file
MMMónica G. Mendoza-Rodríguez
Mónica G. Mendoza-Rodríguez
CSC. Ángel Sánchez-Barrera
C. Ángel Sánchez-Barrera
BCBlanca E. Callejas
Blanca E. Callejas
VGVerónica García-Castillo
Verónica García-Castillo
DBDiana L. Beristain-Terrazas
Diana L. Beristain-Terrazas
Luis I TerrazasLuis I Terrazas
Luis I Terrazas
Colorectal cancer (CRC) is one of the most widespread and deadly types of neoplasia around the world, where the inflammatory microenvironment has critical importance in the process of tumor growth, metastasis, and drug resistance. Despite its limited effectiveness, 5-fluorouracil (5-FU) is the main drug utilized for CRC treatment. The combination of 5-FU with other agents modestly increases its effectiveness in patients. Here, we evaluated the anti-inflammatory Trimethylglycine and the Signal transducer and activator of transcription (STAT6) inhibitor AS1517499, as possible adjuvants to 5-FU in already established cancers, using a model of colitis-associated colon cancer (CAC). We found that these adjuvant therapies induced a remarkable reduction of tumor growth when administrated together with 5-FU, correlating with a reduction in STAT6-phosphorylation. This reduction upgraded the effect of 5-FU by increasing both levels of apoptosis and markers of cell adhesion such as E-cadherin, whereas decreased epithelial–mesenchymal transition markers were associated with aggressive phenotypes and drug resistance, such as β-catenin nuclear translocation and Zinc finger protein SNAI1 (SNAI1). Additionally, Il-10, Tgf-β, and Il-17a, critical pro-tumorigenic cytokines, were downmodulated in the colon by these adjuvant therapies. In vitro assays on human colon cancer cells showed that Trimethylglycine also reduced STAT6-phosphorylation. Our study is relatively unique in focusing on the effects of the combined administration of AS1517499 and Trimethylglycine together with 5-FU on already established CAC which synergizes to markedly reduce the colon tumor load. Together, these data point to STAT6 as a valuable target for adjuvant therapy in colon cancer.

9 February 2021 in Genes
Verified
Journal Article
Open access
PDF file
RSRebeca Salgado
Rebeca Salgado
JCJossimar Coronel-Hernández
Jossimar Coronel-Hernández
IDIzamary Delgado-Waldo
Izamary Delgado-Waldo
DLDavid Cantú De León
David Cantú De León
VGVerónica García-Castillo
Verónica García-Castillo
NJNadia Jacobo-Herrera
Nadia Jacobo-Herrera
Colorectal cancer (CRC) is among the top three most deadly cancers worldwide. The survival rate for this disease has not been reduced despite the treatments, the reason why the search for therapeutic alternatives continues to be a priority issue in oncology. In this research work, we tested our successful pharmacological combination of three drugs, metformin, doxorubicin, and sodium oxamate (triple therapy, or TT), as an autophagy inducer. Firstly, we employed western blot (WB) assays, where we observed that after 8 h of stimulation with TT, the proteins Unc-51 like autophagy activating kinase 1(ULK1), becline-1, autophagy related 1 protein (Atg4), and LC3 increased in the CRC cell lines HCT116 and SW480 in contrast to monotherapy with doxorubicin. The overexpression of these proteins indicated the beginning of autophagy flow through the activation of ULK1 and the hyperlipidation of LC3 at the beginning of this process. Moreover, we confirm that ULK1 is a bona fide target of hsa-miR-106a-5p (referred to from here on as miR-106a) in HCT116. We also observed through the GFP-LC3 fusion protein that in the presence of miR-106a, the accumulation of autophagy vesicles in cells stimulated with TT is inhibited. These results show that the TT triggered autophagy to modulate miR-106a/ULK1 expression, probably affecting different cellular pathways involved in cellular proliferation, survivance, metabolic maintenance, and cell death. Therefore, considering the importance of autophagy in cancer biology, the study of miRNAs that regulate autophagy in cancer will allow a better understanding of malignant tumors and lead to the development of new disease markers and therapeutic strategies.

26 April 2017 in Tumor Biology
Verified
Journal Article
Open access
Eduardo López-UrrutiaEduardo López-Urrutia
Eduardo López-Urrutia
JCJossimar Coronel-Hernández
Jossimar Coronel-Hernández
VGVerónica García-Castillo
Verónica García-Castillo
CCCarlos Contreras-Romero
Carlos Contreras-Romero
AGAntonio Martinez Gutierrez
Antonio Martinez Gutierrez
Carlos Pérez-PlasenciaCarlos Pérez-Plasencia
Carlos Pérez-Plasencia
MicroRNAs are non-coding short RNAs that target the 3′ untranslated region of messenger RNAs (mRNAs) and lead to their degradation or to translational repression. Several microRNAs have been designated as oncomirs, owing to their regulating tumor suppressor genes. Interestingly, a few of them have been found to target multiple genes whose simultaneous suppression contributes to the development of a tumoral phenotype. Here, we have showed that miR-26a is overexpressed in colorectal cancer data obtained from TCGA Research Network and in human colon cancer pathological specimens; moreover, an orthotopic in vivo model of colon cancer showed overexpression of miR-26a, while Rb1 expression inversely correlated to miR-26a in TCGA Research Network data, pathological samples, and the in vivo model. Then, by means of luciferase assay, we demonstrated that miR-26a targets the 3′ untranslated region of Rb1 mRNA directly. This is, to our knowledge, the first report of miR-26a targeting Rb1 in colon cancer. The results of this study suggested that miR-26a could serve as a progression biomarker in colorectal cancer. Further validation studies are still needed to confirm our findings.

1 January 2016 in Journal of Cancer
Verified
Journal Article
Open access
Gabriela Figueroa-GonzálezGabriela Figueroa-González
Gabriela Figueroa-González
VGVerónica García-Castillo
Verónica García-Castillo
JCJossimar Coronel-Hernández
Jossimar Coronel-Hernández
Eduardo López-UrrutiaEduardo López-Urrutia
Eduardo López-Urrutia
SONIA LEON-CABRERASONIA LEON-CABRERA
SONIA LEON-CABRERA
Carlos Pérez-PlasenciaCarlos Pérez-Plasencia
Carlos Pérez-Plasencia
Colorectal cancer (CRC) is an important health issue worldwide, accounting for the third place of cancer incidence. Chronic inflammation, as seen in Crohn's disease and ulcerative colitis, is the most important risk factor for developing CRC, as it favours neoplastic transformation by enhancing epithelial cell turnover in the colonic mucosa. Treatments for CRC need to be improved; currently they are not specific and have several secondary effects in patients. The main objective of this work was to evaluate a new therapeutic strategy against a colitis-related colorectal cancer in vivo and in vitro by targeting mTOR-signaling and lactate dehydrogenase A. Together, these mechanisms directly affect tumor energetics. In this study we evaluated a better and more efficient triple therapy against a chronic inflammation-associated CRC in vivo and in vitro. After the development of tumors, mice were treated intraperitoneally during a forty-day period with single drugs or different combinations of Metformin, Sodium Oxamate and Doxorubicin.